FDA expands use of Gilead's COVID drug remdesivir to non-hospitalized patients
humonia/iStock via Getty Images


Gilead's (NASDAQ:GILD) COVID-19 treatment Veklury (remdesivir) can now be used in non-hospitalized adults and adolescents at high risk of progressing to severe disease.
The FDA late Friday approved the company's supplemental New Drug Application for the antiviral.

The additional indication means Veklury can be administered as daily intravenous infusions in an outpatient setting over three days.
The expanded approval was supported by results from the phase 3 PINETREE trial, which found that there was an 87% risk reduction in COVID-19-related hospitalization or all-cause death by day 28 compared to placebo.